These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19221367)

  • 21. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs.
    Pediatrics; 1996 Jul; 98(1):143-5. PubMed ID: 8668390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-year Medicare Part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients.
    West JC; Wilk JE; Rae DS; Muszynski IL; Rubio-Stipec M; Alter CL; Sanders KE; Crystal S; Regier DA
    J Clin Psychiatry; 2010 Apr; 71(4):400-10. PubMed ID: 19925748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rising Cost of Anticancer Medications in the United States.
    Jackson K; Nahata MC
    Ann Pharmacother; 2017 Aug; 51(8):706-710. PubMed ID: 28707550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
    Academy of Managed Care Pharmacy
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence and cost of unapproved uses of top-selling orphan drugs.
    Kesselheim AS; Myers JA; Solomon DH; Winkelmayer WC; Levin R; Avorn J
    PLoS One; 2012; 7(2):e31894. PubMed ID: 22363762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
    Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
    J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.
    Kocs D; Fendrick AM
    Am J Manag Care; 2003 May; 9(5):393-400; quiz 401-2. PubMed ID: 12744301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using the MADIT II criteria for implantable cardioverter defibrillators-what is the role of the Food and Drug Administration approval?
    Barold HS
    Card Electrophysiol Rev; 2003 Dec; 7(4):443-6. PubMed ID: 15071272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Off-label use reimbursement.
    Cohen J; Wilson A; Faden L
    Food Drug Law J; 2009; 64(2):391-403. PubMed ID: 19999289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Off-label prescribing among office-based physicians.
    Radley DC; Finkelstein SN; Stafford RS
    Arch Intern Med; 2006 May; 166(9):1021-6. PubMed ID: 16682577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs.
    O'Reilly J; Dalal A
    Ann Health Law; 2003; 12(2):295-324, table of contents. PubMed ID: 12856461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medicare Part D: selected issues for plan sponsors, pharmacists, and beneficiaries in 2009.
    Stubbings J; DePue RJ
    Am J Manag Care; 2009 Sep; 15(9):645-9. PubMed ID: 19747029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.
    Wang B; Studdert DM; Sarpatwari A; Franklin JM; Landon J; Kesselheim AS
    PLoS One; 2017; 12(4):e0175313. PubMed ID: 28388667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Introduction: on-label and off-label drug use in reproductive medicine.
    Legro RS
    Fertil Steril; 2015 Mar; 103(3):581-2. PubMed ID: 25726701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
    Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
    J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Off-label uses of drugs and medical devices: should the FDA crack down?
    Margolis RE
    Healthspan; 1993 Jan; 10(1):18-9. PubMed ID: 10124289
    [No Abstract]   [Full Text] [Related]  

  • 38. Origins of the prohibition against off-label promotion.
    Coleman TS
    Food Drug Law J; 2014; 69(2):161-236, i. PubMed ID: 25163210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs.
    Cohen J; Malins A; Shahpurwala Z
    Health Aff (Millwood); 2013 Apr; 32(4):762-70. PubMed ID: 23569057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.